CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 112 enrolled
Drug / intervention
Neuroprotective goal directed hemodynamic optimization +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02541591
NCT02541591N/ACompleted
CompareCT.gov

Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients: a Randomized Controlled Trial (the NEUROPROTECT Post-CA Trial)

Universitaire Ziekenhuizen KU Leuven·interventional·Posted Sep 4, 2015·Updated Apr 12, 2024

In Brief

A clinical study evaluating Neuroprotective goal directed hemodynamic optimization and MAP > 65mmHg for Cerebral Ischemia and Cardiac Arrest. Completed, enrolled 112 participants across 2 sites.

Detailed Summary

The primary objective of the Neuroprotect trial is to assess whether or not a new goal directed hemodynamic optimization strategy can reduce cerebral ischemia in post-cardiac arrest (CA) patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Ischemia, Cardiac Arrest
CountriesBelgium
CollaboratorsZiekenhuis Oost-Limburg

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 4, 2015
Enrollment StartAug 1, 2015
Primary CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.8 years ago

Interventions

Neuroprotective goal directed hemodynamic optimizationother

MAP > 65mmHgother

MAP \> 65mmHg